Nov 07, 2024
Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Aug 07, 2024
Relmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Jun 18, 2024
Relmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The Journal of Clinical Psychiatry
Jun 10, 2024
Relmada Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Jun 03, 2024
Relmada Therapeutics to Participate in the 2024 Jefferies Global Healthcare Conference
May 06, 2024
Relmada Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024
Mar 19, 2024
Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
Mar 12, 2024
Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024
Mar 05, 2024
Relmada Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
Jan 04, 2024
Relmada Therapeutics Provides Corporate Update
Feb 23, 2021
Relmada Therapeutics Announces Participation in the 2021 SVB Leerink Global Healthcare Conference
Dec 07, 2020
Relmada Therapeutics Announces Initiation of Phase 3 Program for REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder
Nov 17, 2020
Relmada Therapeutics to Participate in Upcoming Investor Conferences
Jul 13, 2020
Relmada Therapeutics Announces Uplisting to the Nasdaq Global Select Market®
Jun 23, 2020
Relmada Therapeutics Announces Notice of Allowance for Patent in Canada Covering REL-1017 for Treatment of Psychiatric Symptoms
May 27, 2020
Relmada Therapeutics Announces Outcome of End-of-Phase 2 Meeting with FDA for REL-1017 for Adjunctive Treatment of Patients with Major Depressive Disorder
Apr 28, 2020
Relmada Therapeutics Enhances Senior Leadership Team with Appointment of Brian A. Walter, Ph.D., as Vice President of Regulatory Affairs
Mar 31, 2020
Relmada Therapeutics Solidifies its R&D Leadership Team with the Appointment of Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety
Mar 24, 2020
Relmada Therapeutics Strengthens Scientific Leadership Team with the Appointment of Judy Caron, Ph.D., as Vice President of Drug Development
Feb 25, 2020
Relmada Therapeutics to Present at 9th Annual SVB Leerink Global Healthcare Conference